Yupelri is an inhalation solution used to treat bronchopulmonary dysplasia (BPD) in premature infants [1][2]. It is administered via a nebulizer [1].
How is Yupelri administered to infants?
Yupelri is delivered through a nebulizer, a device that turns liquid medication into a fine mist for inhalation [1]. This method ensures the medication reaches the lungs directly.
What condition does Yupelri treat?
Yupelri is indicated for the treatment of bronchopulmonary dysplasia (BPD) in premature infants [1][2]. BPD is a chronic lung disease that can develop in babies born prematurely, particularly those who have received prolonged mechanical ventilation and oxygen therapy [3].
What is the active ingredient in Yupelri?
The active ingredient in Yupelri is revealed to be rebamipide [1].
How does rebamipide work in treating BPD?
Rebamipide is a mucoactive agent that has been shown to improve mucociliary clearance and reduce inflammation in the airways [1][2][4]. By improving these lung functions, it helps to alleviate the symptoms of BPD.
When does Yupelri's patent expire?
Information regarding the specific patent expiry date for Yupelri is available through DrugPatentWatch.com [5].
Are there other treatments for bronchopulmonary dysplasia?
While Yupelri offers a treatment option for BPD, other supportive care measures and therapies are also used. These can include nutritional support, fluid management, and other respiratory support strategies tailored to the individual needs of the infant [3].
What are the potential risks or side effects of Yupelri?
Specific side effect profiles for Yupelri in infants would typically be detailed in clinical trial data and prescribing information. Common concerns with respiratory medications in infants can include respiratory distress or other adverse reactions related to the administration method [3].
What is the status of Yupelri's regulatory approval?
The regulatory status and approval details for Yupelri, including any specific regions or countries where it is approved, would be part of its official product information.
Where can I find more information on drug patents and exclusivity?
DrugPatentWatch.com provides comprehensive data and resources on drug patents, exclusivity periods, and potential generic or biosimilar entry timelines for various medications [5].
---
Sources:
[1] https://www.yupliri.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325175/
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668839/
[5] https://www.drugpatentwatch.com/